Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
Phase 2/3
45
about 5.1 years
18+
1 site in MA
What this study is about
This trial is testing how different treatments affect skin inflammation in people with allergic contact dermatitis. It uses a model of skin inflammation and biologic medications like adalimumab, betamethasone valerate, canakinumab, dupilumab, fluticasone propionate, guselkumab, sarilumab, ustekinumab, and triamcinolone acetonide to understand how these treatments work in the skin.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Adalimumab
- 2.Take Betamethasone Valerate
- 3.Take Canakinumab
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
adalimumab (Monoclonal antibody; blocks TNF-alpha to reduce inflammation), Antineoplastic Agent [TC] (Corticosteroid Hormone Receptor Agonists), canakinumab, dupilumab, Respiratory System Agent (Corticosteroid Hormone Receptor Agonists), guselkumab, sarilumab, Anti-inflammatory Agent (Corticosteroid Hormone Receptor Agonists)
injection, oral (Oral Tablet), subcutaneous, topical (Topical Lotion), intravenous, injection (Injection)
biopsy
Dermatology